Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

• the present invention relates to a novel thiazolidine-2,4-dione derivative having a hypoglycemic action and an aldose reductase inhibitory action, a salt thereof, a method for producing the same, and a drug containing the same.
• biguanide compounds and sulfonylprea compounds have been used as therapeutic agents for diabetes.
• biguanide compounds cause lactic acidosis, and sulfonylurea compounds cause severe hypoglycemia, and their side effects are problematic. Is desired.
• R represents a hydrogen atom, a lower alkyl group, a hydroxyl group, an alkoxy group, a nitro group, an amino group, a lower acylamino group, a halogen, and a trifluoromethyl group.
• R 1 and R 2 are the same or different and are a hydrogen atom, a halogen, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a nitro group or an amino group
• R 3 represents a hydrogen atom or a lower alkyl group
• A represents a lower alkylene or a carbonyl group
• B and W are different and represent a lower alkylene, a carbonyl group or a bond.
• An object of the present invention is to provide a compound which has an excellent hypoglycemic effect and at the same time has a potent aldose reductase inhibitory effect, and which is useful as an effective and highly safe drug capable of preventing and treating diabetes and its complications. It is to provide Disclosure of the invention
• R 1 and R are the same or different and each represents a hydrogen atom, a halogen, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a nitro group or an amino group (the amino group is a lower alkyl group or a lower alkyl group; Represents a hydrogen atom or a lower alkyl group, A represents a lower alkylene or a carbonyl group, and B and W differently represent a lower alkylene, a carbonyl group or a bond . It has been found that the thiazolidin-2,4-dione derivative or a salt thereof has an excellent hypoglycemic action and an aldose reductase inhibitory action, and completed the present invention.
• lower alkyl as used in the present invention means a straight or branched one having 1 to 6 carbon atoms such as methyl, ethyl, n-butyl, isopropyl and the like. Is mentioned. "Halogen” includes fluorine, chlorine, bromine and iodine.
• the “lower alkoxy” includes straight or branched ones having 1 to 6 carbon atoms such as methoxy, ethoxy, n-propoxy, and isopropoxy.
• the “lower alkanol” includes those having 1 to 4 carbon atoms such as acetyl and propionyl.
• “Lower alkylene” has 1 to 3 carbon atoms and includes methylene, ethylene, trimethylene and the like. "Leaving group” is halogen, lower alkoxy or hydroxy, preferably halogen.
• the “salt” is a pharmaceutically acceptable salt, for example, a cation such as sodium or potassium, an inorganic acid (such as hydrochloric acid or sulfuric acid) or an organic acid (such as p-toluenesulfonic acid). May be included.
• the cyclization can be performed in the presence of a base or an acid.
• the base include an alkali metal alkoxide such as sodium methoxide, and an alkali metal hydride such as sodium hydride, for example, in a temperature range from room temperature to the boiling point of the solvent.
• the acid is, for example, an organic acid such as acetic acid or p-toluenesulfonic acid, or an inorganic acid such as hydrochloric acid or hydrobromic acid. Usually, an excess amount of the acid is used under heating. Both are carried out in a solvent inert to the reaction, such as methanol, ethanol, or dimethylformamide.
• the compound represented by the general formula (1) is a compound represented by the general formula (2)
• Z represents a leaving group
• R 1 , A, B, and W can be obtained by reacting the compound shown above with an appropriate base.
• This reaction is carried out in a solvent such as dioxane, dimethylformamide, or ethyl acetate, and as a base, an alkali metal hydride such as sodium hydride, or an alkali metal hydride such as sodium hydroxide.
• the reaction can be advantageously carried out in the presence of an oxide, for example, an alkali metal carbonate such as carbon dioxide, for example, an organic base such as pyridine or triethylamine.
• the reaction temperature is in the range of 40 to 12 G ° C, and the reaction is completed in 1 to 5 hours.
• the compound represented by the general formula (1) is a compound represented by the general formula (2) and the compound represented by the general formula (6)
• a pharmaceutically acceptable salt of the compound represented by (1) may be prepared by a conventional method such as sodium hydroxide, It can be obtained by reacting with a base coexisting with a cation, for example, an inorganic acid such as hydrochloric acid or sulfuric acid, or an organic acid such as fumaric acid-oxalic acid.
• Rats were orally administered the compound of Example 1 at a dose of lOmgZkg for 5 days and then fasted for an hour. Thereafter, insulin was administered intraperitoneally at a dose of 0.1 knit Zkg, and blood was collected from the tail vein at 0 and 1 hour after insulin administration to quantify blood glucose (Table 1).
• the compound of Example 1 was orally administered to hereditary obese mice (CS57BL ob / ob) at doses of 1 ⁇ , 30 and 100 mgZkg for 5 hours and then fasted for 8 hours. Thereafter, glucose was orally administered at a dose of 2 gZkg, and blood was collected from the tail vein at 0, 30, 60 and 120 minutes after the administration, and blood glucose was quantified (Table 2). These results indicate that the compound of the present invention exhibits a potent hypoglycemic effect.
• novel thiazolidine-2,4-dione derivative and salts thereof according to the present invention not only have excellent hypoglycemic activity, but also have remarkable aldose reducing enzyme inhibitory activity, and are useful for treating diabetes and its complications. It is useful as a preventive drug.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Diabetes (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Emergency Medicine (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Endocrinology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Indole Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=12938273

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (3)

Citations (3)

• 1991
  • 1991-02-25 JP JP3053278A patent/JPH04270273A/ja active Pending
• 1992
  • 1992-02-24 EP EP92905306A patent/EP0527232B1/en not_active Expired - Lifetime
  • 1992-02-24 ES ES92905306T patent/ES2123549T3/es not_active Expired - Lifetime
  • 1992-02-24 AU AU12460/92A patent/AU645177B2/en not_active Ceased
  • 1992-02-24 KR KR1019920702623A patent/KR960007533B1/ko not_active Expired - Fee Related
  • 1992-02-24 CA CA002081112A patent/CA2081112A1/en not_active Abandoned
  • 1992-02-24 TW TW081101365A patent/TW202447B/zh active
  • 1992-02-24 US US07/938,228 patent/US5308856A/en not_active Expired - Lifetime
  • 1992-02-24 HU HU9203293A patent/HU218662B/hu not_active IP Right Cessation
  • 1992-02-24 DK DK92905306T patent/DK0527232T3/da active
  • 1992-02-24 AT AT92905306T patent/ATE171450T1/de not_active IP Right Cessation
  • 1992-02-24 WO PCT/JP1992/000190 patent/WO1992014730A1/ja not_active Ceased
  • 1992-02-24 DE DE69227081T patent/DE69227081T2/de not_active Expired - Fee Related

Patent Citations (3)

Also Published As

Similar Documents

Legal Events